Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIFLUOX-DP
2023-508724-35-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil in colorectal adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Unicancer. Primary endpoints: Rate of patients without specific early toxicities and Disease control rate at first evaluation. Planned start Jul 2024; status: authorised.
02
Drugs
trifluridine + tipiracil
03
Conditions
colorectal adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-508724-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508724-35-00.